TREATMENT OF PSORIASIS WITH 6‐THIOGUANINE

Authors:

Abstract
Summary: Fifty‐four patients with Psoriasis were treated with the antimetabolite, 6‐thioguanine (TG). Three were early drop‐outs due to side effects. Of 48 evaluable patients with plaque‐type lesions, mostly extensive, 79% achieved over 75% improvement as an initial response, 8% had over 50% improvement and 13% had less than 50% improvement. 65% retained at least 50% improvement in follow‐up periods of up to 21 years, median 13 months. Two of three patients with palmar‐plantar pustular psoriasis had over 50% improvement. Myelosuppression was the most common side effect, occurring in 57% of the patients. One woman experienced pancytopenia from which she recovered. One man developed an acute, short‐lived hepatitis. In general, TG was better tolerated than methotrexate (MTX) and was more effective than MTX in the majority of patients who had changed from MTX due to inadequate response or side effects. TG should be considered as an alternative therapy for MTX, retinoids, or PUVA failures or exclusions.

This publication has 8 references indexed in Scilit: